Generate:Biomedicines

Generate:Biomedicines is a biotechnology company that uses AI to engineer novel therapeutics, including monoclonal antibodies like GB-0895 for asthma treatment.

Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion

October 15, 2026

Zealand Pharma will use Generate:Biomedicines' generative AI platform to develop protein treatments for obesity and metabolic diseases under a deal worth up to $1.2 billion.

Generate:Biomedicines to Present Phase 1 Results for AI-Engineered Asthma Treatment

September 26, 2025

Generate:Biomedicines will present Phase 1 results for its AI-engineered asthma treatment, GB-0895, at the European Respiratory Society International Congress.
Free newsletter

Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates